Is amoxicillin safe to use in patients with myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amoxicillin and Myasthenia Gravis

Amoxicillin can be used in patients with myasthenia gravis, but requires close monitoring as it has been documented to cause acute exacerbations in some patients, despite penicillins traditionally being considered safer than other antibiotic classes like fluoroquinolones, aminoglycosides, and macrolides. 1, 2

Risk Assessment

While current guidelines specifically warn against fluoroquinolones, aminoglycosides, and macrolide antibiotics in MG patients 1, 3, amoxicillin is notably absent from these high-risk lists. However, clinical evidence demonstrates a real risk:

  • A case series documented six MG patients who developed acute worsening of symptoms after amoxicillin or amoxicillin/clavulanate treatment, with symptoms starting within a few days of antibiotic administration 2
  • All six patients experienced worsening of their MGFA clinical classification and required therapeutic intervention with dosage increases or new medications 2
  • Historical data from 1986 showed ampicillin (a closely related penicillin) aggravated symptoms in myasthenic patients and increased electrical decrements in experimental autoimmune MG 4

Clinical Decision-Making Algorithm

If amoxicillin is chosen for infection treatment in an MG patient:

  • Baseline assessment: Measure negative inspiratory force (NIF) and vital capacity (VC) before starting treatment, applying the "20/30/40 rule" (VC <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O indicates high risk) 3

  • Daily monitoring: Perform daily neurological evaluation focusing on muscle strength, bulbar symptoms (speech, swallowing difficulties), diplopia, and ptosis 1, 3

  • Respiratory surveillance: Monitor respiratory function frequently, especially in patients with generalized MG (MGFA class III-V), as pulse oximetry and arterial blood gases may not capture early decompensation 3

When to Avoid Amoxicillin

Consider alternative antibiotics if:

  • The patient has a history of previous MG exacerbation with penicillins 2, 5
  • The patient has compromised baseline respiratory function (meeting the 20/30/40 rule criteria) 3
  • The patient has symptomatic, generalized MG, as these patients are especially vulnerable to drug-induced exacerbations 6

Management of Exacerbation

If the patient deteriorates on amoxicillin:

  • Immediately discontinue the antibiotic 2
  • Hospitalize for ICU-level monitoring if respiratory compromise develops 3
  • Administer high-dose corticosteroids: methylprednisolone 1-2 mg/kg/day IV 3
  • Initiate rapid immunomodulation with either plasmapheresis (5 sessions over 5 days) OR IVIG (2 g/kg total dose over 5 days) 3
  • Most patients achieve full recovery to baseline within 1-2 months after discontinuation 2

Critical Pitfall

The major clinical trap is assuming all penicillins are completely safe in MG simply because they are not listed among the highest-risk antibiotics. 2, 4 While amoxicillin carries lower risk than fluoroquinolones or aminoglycosides, it is not risk-free and requires vigilant monitoring, particularly in patients with generalized or symptomatic disease 6.

References

Guideline

Medications to Avoid in Myasthenia Gravis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Exacerbation of myasthenia gravis after amoxicillin therapy: a case series.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020

Guideline

Management of Myasthenia Gravis in Patients Receiving Paxlovid

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Drugs that may trigger or exacerbate myasthenia gravis].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.